PH12018501077B1 - N-substituted indole derivatives as pge2 receptor modulators - Google Patents
N-substituted indole derivatives as pge2 receptor modulatorsInfo
- Publication number
- PH12018501077B1 PH12018501077B1 PH12018501077A PH12018501077A PH12018501077B1 PH 12018501077 B1 PH12018501077 B1 PH 12018501077B1 PH 12018501077 A PH12018501077 A PH 12018501077A PH 12018501077 A PH12018501077 A PH 12018501077A PH 12018501077 B1 PH12018501077 B1 PH 12018501077B1
- Authority
- PH
- Philippines
- Prior art keywords
- receptor modulators
- indole derivatives
- substituted indole
- pge2 receptor
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015077269 | 2015-11-20 | ||
| PCT/EP2016/078028 WO2017085198A1 (en) | 2015-11-20 | 2016-11-17 | N-substituted indole derivatives as pge2 receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12018501077A1 PH12018501077A1 (en) | 2019-01-28 |
| PH12018501077B1 true PH12018501077B1 (en) | 2019-01-28 |
Family
ID=57326428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018501077A PH12018501077B1 (en) | 2015-11-20 | 2018-05-18 | N-substituted indole derivatives as pge2 receptor modulators |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11241431B2 (OSRAM) |
| EP (2) | EP3377483B9 (OSRAM) |
| JP (2) | JP2018534328A (OSRAM) |
| KR (1) | KR102352022B1 (OSRAM) |
| CN (1) | CN108349949B (OSRAM) |
| AU (1) | AU2016358242B2 (OSRAM) |
| BR (1) | BR112018010291B1 (OSRAM) |
| CA (1) | CA3002610C (OSRAM) |
| CL (1) | CL2018001325A1 (OSRAM) |
| CO (1) | CO2018005715A2 (OSRAM) |
| CR (1) | CR20180323A (OSRAM) |
| CY (1) | CY1124913T1 (OSRAM) |
| DK (2) | DK3928836T3 (OSRAM) |
| EA (1) | EA037953B1 (OSRAM) |
| ES (2) | ES2994636T3 (OSRAM) |
| FI (1) | FI3928836T3 (OSRAM) |
| HR (2) | HRP20211678T1 (OSRAM) |
| HU (2) | HUE056679T2 (OSRAM) |
| IL (1) | IL259424B (OSRAM) |
| LT (2) | LT3928836T (OSRAM) |
| MA (2) | MA43251B1 (OSRAM) |
| MX (1) | MX375978B (OSRAM) |
| MY (1) | MY195888A (OSRAM) |
| PE (1) | PE20181304A1 (OSRAM) |
| PH (1) | PH12018501077B1 (OSRAM) |
| PL (2) | PL3377483T3 (OSRAM) |
| PT (2) | PT3928836T (OSRAM) |
| RS (2) | RS62598B1 (OSRAM) |
| SA (1) | SA518391588B1 (OSRAM) |
| SG (1) | SG11201803627XA (OSRAM) |
| SI (2) | SI3928836T1 (OSRAM) |
| TW (2) | TWI719078B (OSRAM) |
| UA (1) | UA123441C2 (OSRAM) |
| WO (1) | WO2017085198A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) * | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| HUE069643T2 (hu) | 2017-03-27 | 2025-03-28 | Hydro Quebec | Elektrolitkeverékekben vagy elektródaadalékként való felhasználásra szánt sók |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| LT3625222T (lt) | 2017-05-18 | 2021-11-10 | Idorsia Pharmaceuticals Ltd | Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| PT3625228T (pt) | 2017-05-18 | 2021-09-16 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores dos recetores de pge2 |
| CN109678780A (zh) * | 2017-10-19 | 2019-04-26 | 中国石油化工股份有限公司 | 一种制备3-烷基吲哚衍生物的方法 |
| CA3084581A1 (en) | 2017-11-20 | 2019-05-23 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3735419A4 (en) | 2018-01-05 | 2021-09-15 | Icahn School of Medicine at Mount Sinai | PROCESS FOR INCREASING THE PROLIFERATION OF PANCREATIC BETA CELLS, PROCESS OF TREATMENT AND COMPOSITION |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US20220064146A1 (en) * | 2018-12-31 | 2022-03-03 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3693359A1 (en) | 2019-02-08 | 2020-08-12 | Medibiofarma, S.L. | New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators |
| WO2021060281A1 (ja) * | 2019-09-24 | 2021-04-01 | Ａｇｃ株式会社 | プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト |
| US11566007B2 (en) | 2019-11-04 | 2023-01-31 | Revolution Medicines, Inc. | Ras inhibitors |
| CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
| JPWO2022102731A1 (OSRAM) | 2020-11-13 | 2022-05-19 | ||
| EP4359399A4 (en) | 2021-06-24 | 2025-04-23 | Reservoir Neuroscience, Inc. | EP2 antagonist compounds |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| JP2003528144A (ja) | 2000-03-24 | 2003-09-24 | ファーマジーン ラボラトリーズ リミテッド | 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| EP1494667A1 (en) | 2002-04-12 | 2005-01-12 | Pfizer Japan Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
| EP1495005A1 (en) | 2002-04-12 | 2005-01-12 | Pfizer Japan Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
| JP2006506327A (ja) | 2002-05-23 | 2006-02-23 | セラテクノロジーズ インコーポレイティド | プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド |
| CN100408570C (zh) | 2003-01-29 | 2008-08-06 | 阿斯特兰德英国有限公司 | Ep4受体拮抗剂 |
| TW200519116A (en) | 2003-08-26 | 2005-06-16 | Teijin Pharma Ltd | Pyrrolopyrimidine derivatives |
| AP2006003534A0 (en) | 2003-09-03 | 2006-04-30 | Pfizer | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists. |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| BRPI0510666A (pt) | 2004-05-04 | 2007-12-04 | Pfizer | compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação |
| JP4054369B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | オルト置換アリールまたはヘテロアリールアミド化合物 |
| HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| AU2006246930C1 (en) | 2005-05-19 | 2012-01-19 | Merck Canada Inc. | Quinoline derivatives as EP4 antagonists |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| AR060403A1 (es) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
| JP5244091B2 (ja) | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体 |
| EP2035376B1 (en) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| CA2657227A1 (en) | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
| EP2054401B1 (en) | 2006-08-11 | 2013-05-01 | Merck Canada Inc. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| WO2008104055A1 (en) | 2007-02-26 | 2008-09-04 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| EP2141147A1 (en) | 2007-03-26 | 2010-01-06 | Astellas Pharma Inc. | Ornithine derivative |
| CA2681146A1 (en) | 2007-03-26 | 2008-10-02 | Merck Frosst Canada Ltd. | Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| CN101889004B (zh) | 2007-10-12 | 2014-09-10 | 阿斯利康公司 | 蛋白激酶抑制剂 |
| CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| SI2565191T1 (sl) | 2008-05-14 | 2014-12-31 | Astellas Pharma Inc. | Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| US8404736B2 (en) | 2008-08-14 | 2013-03-26 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as EP4 receptor antagonists |
| CN102164942B (zh) | 2008-09-19 | 2017-02-15 | 生物科技研究有限公司 | 三萜系化合物及其使用的方法 |
| JP2012503605A (ja) | 2008-09-25 | 2012-02-09 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体 |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| WO2011063181A1 (en) | 2009-11-23 | 2011-05-26 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
| JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
| PT2619182T (pt) | 2010-09-21 | 2017-01-17 | Eisai R&D Man Co Ltd | Composição farmacêutica |
| KR101857310B1 (ko) | 2010-09-29 | 2018-05-11 | 가부시키가이샤 에누비 켄코우겡큐쇼 | 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체 |
| BR112013012380A2 (pt) | 2010-11-17 | 2016-08-30 | Novartis Ag | compostos 3-(aminoaril)-piridina |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
| EP2702043A1 (en) | 2011-04-29 | 2014-03-05 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
| US9518044B2 (en) | 2011-06-20 | 2016-12-13 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| US9181279B2 (en) | 2011-07-04 | 2015-11-10 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor antagonists |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
| JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2711364A1 (en) * | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| MY182386A (en) | 2012-11-27 | 2021-01-22 | Thomas Helledays Stiftelse For Medicinsk Forskning | Pyrimidine-2,4-diamine derivatives for treatment of cancer |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| SG11201510121RA (en) | 2013-06-12 | 2016-01-28 | Kaken Pharma Co Ltd | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
| AU2014315457B2 (en) | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP6521977B2 (ja) | 2013-09-06 | 2019-05-29 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 免疫調節剤としての１，２，４−オキサジアゾール誘導体 |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| CN105636958B (zh) | 2013-10-17 | 2018-01-05 | 沃泰克斯药物股份有限公司 | Dna‑pk抑制剂 |
| SI3424920T1 (sl) | 2013-10-17 | 2020-08-31 | Vertex Pharmaceuticals Incorporated | Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk |
| SI3083554T1 (sl) | 2013-12-17 | 2019-04-30 | Eli Lilly & Company | Spojine dimetilbenzojske kisline |
| DK3083562T3 (da) | 2013-12-17 | 2017-11-13 | Lilly Co Eli | Cykliske phenoxyethylaminderivater og deres aktivitet som EP4-receptormodulatorer |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| US10052332B2 (en) | 2014-04-29 | 2018-08-21 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| CN106572993B (zh) | 2014-05-23 | 2019-07-16 | 卫材R&D管理有限公司 | Ep4拮抗剂在制备治疗癌症的药物中的应用 |
| SG11201609981RA (en) | 2014-06-04 | 2016-12-29 | Thomas Helledays Stiftelse För Medicinsk Forskning | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| TWI712595B (zh) | 2015-01-09 | 2020-12-11 | 日商小野藥品工業股份有限公司 | 三環性螺化合物 |
| CN108368127B (zh) | 2015-07-23 | 2020-12-11 | 武田药品工业株式会社 | 化合物及其作为ep4受体拮抗剂的用途 |
| US10316040B2 (en) | 2015-10-16 | 2019-06-11 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP4219462A1 (en) | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| LT3625224T (lt) | 2017-05-18 | 2021-10-25 | Idorsia Pharmaceuticals Ltd | N-pakeistieji indolo dariniai |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| LT3625222T (lt) | 2017-05-18 | 2021-11-10 | Idorsia Pharmaceuticals Ltd | Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai |
| PT3625228T (pt) | 2017-05-18 | 2021-09-16 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores dos recetores de pge2 |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
-
2015
- 2015-11-20 CR CR20180323A patent/CR20180323A/es unknown
-
2016
- 2016-11-17 CN CN201680066933.8A patent/CN108349949B/zh active Active
- 2016-11-17 WO PCT/EP2016/078028 patent/WO2017085198A1/en not_active Ceased
- 2016-11-17 RS RS20211424A patent/RS62598B1/sr unknown
- 2016-11-17 RS RS20241254A patent/RS66179B1/sr unknown
- 2016-11-17 MX MX2018005268A patent/MX375978B/es active IP Right Grant
- 2016-11-17 ES ES21186831T patent/ES2994636T3/es active Active
- 2016-11-17 EP EP16797577.0A patent/EP3377483B9/en active Active
- 2016-11-17 MA MA43251A patent/MA43251B1/fr unknown
- 2016-11-17 PT PT211868310T patent/PT3928836T/pt unknown
- 2016-11-17 ES ES16797577T patent/ES2897954T3/es active Active
- 2016-11-17 US US15/777,597 patent/US11241431B2/en active Active
- 2016-11-17 HR HRP20211678TT patent/HRP20211678T1/hr unknown
- 2016-11-17 PT PT167975770T patent/PT3377483T/pt unknown
- 2016-11-17 EA EA201891179A patent/EA037953B1/ru unknown
- 2016-11-17 EP EP21186831.0A patent/EP3928836B1/en active Active
- 2016-11-17 LT LTEP21186831.0T patent/LT3928836T/lt unknown
- 2016-11-17 KR KR1020187017474A patent/KR102352022B1/ko active Active
- 2016-11-17 SI SI201631863T patent/SI3928836T1/sl unknown
- 2016-11-17 MY MYPI2018701873A patent/MY195888A/en unknown
- 2016-11-17 LT LTEPPCT/EP2016/078028T patent/LT3377483T/lt unknown
- 2016-11-17 DK DK21186831.0T patent/DK3928836T3/da active
- 2016-11-17 CA CA3002610A patent/CA3002610C/en active Active
- 2016-11-17 FI FIEP21186831.0T patent/FI3928836T3/fi active
- 2016-11-17 AU AU2016358242A patent/AU2016358242B2/en active Active
- 2016-11-17 DK DK16797577.0T patent/DK3377483T3/da active
- 2016-11-17 PE PE2018000994A patent/PE20181304A1/es unknown
- 2016-11-17 SG SG11201803627XA patent/SG11201803627XA/en unknown
- 2016-11-17 HU HUE16797577A patent/HUE056679T2/hu unknown
- 2016-11-17 HR HRP20241521TT patent/HRP20241521T1/hr unknown
- 2016-11-17 JP JP2018526184A patent/JP2018534328A/ja not_active Ceased
- 2016-11-17 PL PL16797577T patent/PL3377483T3/pl unknown
- 2016-11-17 HU HUE21186831A patent/HUE069520T2/hu unknown
- 2016-11-17 UA UAA201806812A patent/UA123441C2/uk unknown
- 2016-11-17 SI SI201631400T patent/SI3377483T1/sl unknown
- 2016-11-17 MA MA55046A patent/MA55046B1/fr unknown
- 2016-11-17 BR BR112018010291-1A patent/BR112018010291B1/pt active IP Right Grant
- 2016-11-17 PL PL21186831.0T patent/PL3928836T3/pl unknown
- 2016-11-18 TW TW105137938A patent/TWI719078B/zh active
- 2016-11-18 TW TW109133855A patent/TWI754397B/zh active
-
2018
- 2018-05-15 SA SA518391588A patent/SA518391588B1/ar unknown
- 2018-05-16 IL IL259424A patent/IL259424B/en active IP Right Grant
- 2018-05-17 CL CL2018001325A patent/CL2018001325A1/es unknown
- 2018-05-18 PH PH12018501077A patent/PH12018501077B1/en unknown
- 2018-05-30 CO CONC2018/0005715A patent/CO2018005715A2/es unknown
-
2021
- 2021-04-13 JP JP2021067831A patent/JP7228618B2/ja active Active
- 2021-11-30 CY CY20211101035T patent/CY1124913T1/el unknown
- 2021-12-13 US US17/549,828 patent/US12011444B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501077A1 (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| PH12019502564A1 (en) | Pyrimidine derivatives as pge2 receptor modulators | |
| PH12019502562B1 (en) | N-substituted indole derivatives | |
| PH12014502540B1 (en) | Benzimidazole-proline derivatives | |
| PH12019500188A1 (en) | Piperidine cxcr7 receptor modulators | |
| PH12019502563A1 (en) | Phenyl derivatives as pge2 receptor modulators | |
| MX364610B (es) | Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida. | |
| JOP20190183A1 (ar) | معدِلات مستقبلات الاستروجين | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| NZ763341A (en) | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators | |
| PH12021553178A1 (en) | Pyridin-3-yl derivatives | |
| PH12018501563A1 (en) | Indane derivatives as mglur7 modulators | |
| TH1901007033A (th) | อนุพันธ์ของอินโดลที่ถูกแทนที่แบบ n |